


Curriculum Vitae

Name	Myung-Ju Ahn, M.D., Ph.D.	
Current Position & Affiliation	Primary Academic Appointments at Sungkyunkwan University Professor, Division of Hemato-Oncology, Department of Medicine	
Country	Korea	

Educational Background

1979-1981	Premedicine College of Natural Science, Hanyang University, KOREA
1981-1985	M.D. College of Medicine Hanyang University, KOREA
1986-1988	Master of Science Thesis: "Chromosomal study in Adult Acute Lymphocytic Leukemia" Graduate School, Hanyang University, KOREA
1988-1991	Ph. D. (Tutor: Jong-Myung Kang, M.D. Ph.D: Hanyang University) Thesis: "B and T cell Abnormalities in Patients with Glomerulonephritis" Graduate School, Hanyang University, KOREA

Professional Experience

1985.3-1986.2	Internship in Medicine Hanyang University Hospital Seoul, KOREA
1986.3-1989.2	Residency in Internal Medicine Hanyang University Hospital Seoul, KOREA

1991.3-1993.2	Clinical fellowship in Hematology-Oncology Asan Medical Center University of Ulsan Seoul, KOREA
1993.3-1995.2	Postdoctoral research fellowship (Tutor: Ethan Dmitrovsky. M.D. Ph.D. at Memorial Sloan-Kettering Cancer Center) Memorial Sloan-Kettering Cancer Center New York, U.S.A.
1995.3-1999.2	Assistant Professor Division of Hematology-Oncology Department of Medicine Hanyang University KURI Hospital Kyunggi-do, KOREA
2000.3- 2004.2	Associate Professor Division of Hematology-Oncology Department of Medicine Hanyang University Hospital Seoul, KOREA
2005.3- 2006.1	Professor Division of Hematology-Oncology Department of Medicine Hanyang University Hospital Seoul, KOREA
2006.2- present	Professor Division of Hematology-oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul, Korea

Professional Organizations

Member, Korean Medical Association
Member, Korean Association of Internal Medicine
Member, Korean Association of Cancer
Member, Korean Association of Clinical Oncology
Member, Korean Association of Hematology

Member, Korean Association of stem cell transplantation
Member, American Association for Cancer Research
Member, American Society of Oncology
Member, International Society of Lung Cancer Association
Member, European Society of Medical Oncology
Member, Korean Cancer Study Group

Main Scientific Publications

(Bold letters in red: first or corresponding author)

1. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, **Ahn MJ**, Mok TSK, Tan DSW, Yang F. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. *J Thorac Oncol*. 2020 Mar;15(3):324-343.
2. Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, **Ahn MJ**, Kim ES, Kerstein D, Groen HJM, Camidge DR. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. *J Thorac Oncol*. 2020 Mar;15(3):404-415.
3. Papadimitrakopoulou VA, Han JY, **Ahn MJ**, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, Huang X, Laus G, Markovets A, Thress KS, Wu YL, Mok T. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. *Cancer*. 2020 Jan 15;126(2):373-380.
4. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, **Ahn MJ**. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. *J Clin Oncol*. 2020 Feb 20;38(6):538-547.
5. Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, **Ahn MJ**, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto

- K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020 Feb;21(2):261-270.
6. Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. *Clin Lung Cancer.* 2020 May;21(3):e182-e190.
 7. Shin HT, Kim NKD, Yun JW, Lee B, Kyung S, Lee KW, Ryu D, Kim J, Bae JS, Park D, Choi YL, Lee SH, **Ahn MJ**, Park K, Park WY. Junction Location Identifier (JuLI): Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology. *J Mol Diagn.* 2020 Mar;22(3):304-318
 8. Lee T, Cho J, Baek CH, Son YI, Jeong HS, Chung MK, Hong SD, Ahn YC, Oh DR, Noh JM, Park K, **Ahn MJ**, Kim HJ, Kim YK, Ko YH. Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. *Head Neck.* 2020 May;42(5):924-938.
 9. Shin S, Choi YS, Jung JJ, Im Y, Shin SH, Kang D, Cho JH, Kim HK, Kim J, Zo JI, Shim YM, Park K, **Ahn MJ**, Ahn YC, Lee G, Cho J, Lee HY, Park HY. Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. *Respir Res.* 2020 Jan 10;21(1):13. doi: 10.1186/s12931-019-1254-0.
 10. Grünwald V, Chirovsky D, Cheung WY, Bertolini F, **Ahn MJ**, Yang MH, Castro G, Berrocal A, Sjoquist K, Kuyas H, Auclair V, Guillaume X, Joo S, Shah R, Harrington K; GLANCE H&N STUDY Investigators. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. *Oral Oncol.* 2020 Jan 21;102:104526. doi: 10.1016/j.oraloncology.2019.104526. [Epub ahead of print]
 11. Sequist LV, Han JY, **Ahn MJ**, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellempgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after

- progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. *Lancet Oncol.* 2020 Mar;21(3):373-386
- 12.Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, **Ahn MJ**, Kim J, Um SW. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. *PLoS One.* 2020 Feb 18;15(2):e0229299
 - 13.Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH, Choi JK. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. *Nat Commun.* 2020 Feb 19;11(1):951
 - 14.Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. *Oncoimmunology.* 2020 Feb 2;9(1):1722023.
 - 15.Lee J, Ku BM, Shim JH, La Choi Y, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. *Jpn J Clin Oncol.* 2020 Feb 21. pii: hyaa019. doi: 10.1093/jjco/hyaa019. [Epub ahead of print]
 - 16.Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. *Cancer.* 2020 Mar 10. doi: 10.1002/cncr.32809. [Epub ahead of print]
 - 17.Lim SH, Sun JM, Hong J, Oh D, Ahn YC, Chung MK, Jeong HS, Son YI, **Ahn MJ**, Baek CH, Park K. Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. *Korean J Intern Med.* 2020 Apr 3. doi: 10.3904/kjim.2019.161. [Epub ahead of print]
 - 18.Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, **Ahn MJ**, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC

- Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2020 Apr 9. doi: 10.1001/jamaoncol.2020.0237.
19. Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, **Ahn MJ**, Park K, Park WY, Lee SH. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. *Ann Oncol.* 2020 Apr 19. pii: S0923-7534(20)39295-4.
20. Kim KH, Kim HK, Kim HD, Kim CG, Lee H, Han JW, Choi SJ, Jeong S, Jeon M, Kim H, Koh J, Ku BM, Park SH, **Ahn MJ**, Shin EC. PD-1 blockade-unresponsive human tumor-infiltrating CD8⁺ T cells are marked by loss of CD28 expression and rescued by IL-15. *Cell Mol Immunol.* 2020 Apr 24.
21. Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With *MET* Exon 14 Skipping. *In Vivo.* 2020 May-Jun;34(3):1399-1406.
22. Byeon S, Cho JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. PD-1 Inhibitors for Non-Small Cell Lung Cancer Patients With Special Issues: Real-world Evidence. *Cancer Med.* 2020 Apr;9(7):2352-2362.
23. Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH, Choi JK. Predicting Clinical Benefit of Immunotherapy by Antigenic or Functional Mutations Affecting Tumour Immunogenicity. *Nat Commun.* 2020 Feb 19;11(1):951.
24. Lee J, Choi Y, Jung HA, Lee SH, Ahn JS, **Ahn MJ**, Park K, Sun JM. Lee J, et al. Outstanding Clinical Efficacy of PD-1/PD-L1 Inhibitors for Pulmonary Pleomorphic Carcinoma. *Eur J Cancer.* 2020 Jun;132:150-158.
25. Bang OY, Chung JW, Lee MJ, Seo WK, Kim GM, **Ahn MJ**; OASIS-Cancer Study Investigators. Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke With Unique Pathomechanisms *J Stroke.* 2020 Jan;22(1):1-10.
26. Dingemans AC, Soo RA, Jazieh AR, Rice SJ, Kim YT, Teo LLS, Warren GW, Xiao SY, Smit EF, Aerts JG, Yoon SH, Veronesi G, De Cobelli F, Ramalingam SS, Garassino MC, Wynes MW, Behera M, Haanen J, Lu S, Peters S, **Ahn MJ**, Scagliotti GV, Adjei AA, Belani CP. Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. *J Thorac Oncol.* 2020 Jul;15(7):1119-1136.

27. Papadimitrakopoulou VA, Han JY, **Ahn MJ**, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, Huang X, Laus G, Markovets A, Thress KS, Wu YL, Mok T. Papadimitrakopoulou VA, et al. Epidermal Growth Factor Receptor Mutation Analysis in Tissue and Plasma From the AURA3 Trial: Osimertinib Versus Platinum-Pemetrexed for T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer. *Cancer*. 2020 Jan 15;126(2):373-380.
28. **Ahn MJ**, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Yates JWT, Brown AP, Mendoza-Naranjo A, Mok T. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. *J Thorac Oncol*. 2020 Apr;15(4):637-648.
29. Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, **Ahn MJ**. TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined With Selumetinib, Savolitinib, or Durvalumab in EGFR-mutant Lung Cancer. *Ann Oncol*. 2020 Apr;31(4):507-516.
30. Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, Choi S, Choi YL, Joung JG, Park WY, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**, Lee HO. Kim N, et al. Single-cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma. *Nat Commun*. 2020 May 8;11(1):2285.
31. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, **Ahn MJ**, Mok TSK, Tan DSW, Yang F. Tan WL, et al. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. *J Thorac Oncol*. 2020 Mar;15(3):324-343. doi:
32. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, **Ahn MJ**. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. *J Clin Oncol*. 2020 Feb 20;38(6):538-547.

33. Remon J, Passiglia F, **Ahn MJ**, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. *J Thorac Oncol*. 2020 Jun;15(6):914-947.
34. Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, **Ahn MJ**, Kim ES, Kerstein D, Groen HJM, Camidge DR. [Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial](#). *J Thorac Oncol*. 2020 Mar;15(3):404-415.
35. Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). *J Clin Oncol*. 2020 Feb 10;38(5):488-495.
36. Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. *Clin Lung Cancer*. 2020 May;21(3):e182-e190
37. Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, **Ahn MJ**, Park K, Esteller M, Lee SH, Choi JK. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. *Nat Commun*. 2019 Sep 19;10(1):4278
38. Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH, Choi JK. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. *Nat Commun*. 2020 Feb 19;11(1):951
39. Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. *Cancer*. 2020 Jun 1;126(11):2704-2712.

40. Lim SH, Sun JM, Hong J, Oh D, Ahn YC, Chung MK, Jeong HS, Son YI, **Ahn MJ**, Baek CH, Park K. Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. *Korean J Intern Med.* 2020 Apr 3
41. Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, **Ahn MJ**, Park K, Park WY, Lee SH. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. *Ann Oncol.* 2020 Jul;31(7):902-911
42. Kim KH, Kim HK, Kim HD, Kim CG, Lee H, Han JW, Choi SJ, Jeong S, Jeon M, Kim H, Koh J, Ku BM, Park SH, **Ahn MJ**, Shin EC. PD-1 blockade-unresponsive human tumor-infiltrating CD8⁺ T cells are marked by loss of CD28 expression and rescued by IL-15. *Cell Mol Immunol.* 2021 Feb;18(2):385-397
43. Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, **Ahn MJ**, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. *J Natl Cancer Inst.* 2020 May 14;113(2):171-81.
44. Lim SM, Kim SW, Cho BC, Kang JH, **Ahn MJ**, Kim DW, Kim YC, Lee JS, Lee JS, Lee SY, Park KU, An HJ, Cho EK, Jang TW, Kim BS, Kim JH, Lee SS, Na II, Yoo SS, Lee KH. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea. *Cancer Res Treat.* 2020 Oct;52(4):1112-1119
45. Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, **Ahn MJ**, Pyo H, Ahn YC, Park K. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. *Lung Cancer.* 2020 Aug;146:23-29.
46. Jung HA, Sun JM, Lee SH, Ahn JS, **Ahn MJ**, Park K. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care; UNIVERSE-ROOT study). *Lung Cancer.* 2020 Aug;146:112-119

47. Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, **Ahn MJ**. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation. *Cancer Res Treat*. 2020 Oct;52(4):1288-1290
48. Park S, Shim J, Mortimer PGS, Smith SA, Godin RE, Hollingsworth SJ, Kim HJ, Jung HA, Sun JM, Park WY, Ahn JS, **Ahn MJ**, Lee SH, Park K. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. *Cancer*. 2020 Sep 1;126(17):4002-4012
49. Lee J, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? *J Thorac Dis*. 2020 Jul;12(7):3796-3803.
50. Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, Lee KH, Cho EK, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. *Ann Oncol*. 2020 Oct;31(10):1397-1404.
51. Koh J, Kim Y, Lee KY, Hur JY, Kim MS, Kim B, Cho HJ, Lee YC, Bae YH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. MDSC subtypes and CD39 expression on CD8⁺ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. *Eur J Immunol*. 2020 Nov;50(11):1810-1819
52. Lee J, Choi Y, Han J, Park S, Jung HA, Su JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. *J Thorac Oncol*. 2020 Nov;15(11):1758-1766
53. Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, **Ahn MJ**, Kim SB, Keam B. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. *J Cancer Res Clin Oncol*. 2020 Dec;146(12):3359-3369.

54. Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Evaluating entrectinib as a treatment option for non-small cell lung cancer. *Expert Opin Pharmacother*. 2020 Nov;21(16):1935-1942
55. Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, Park K, **Ahn MJ**. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. *BMC Cancer*. 2020 Aug 5;20(1):727
56. Kim G, Kim J, Cha H, Park WY, Ahn JS, **Ahn MJ**, Park K, Park YJ, Choi JY, Lee KH, Lee SH, Moon SH. Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. *Sci Rep*. 2020 Aug 6;10(1):13231.
57. Camidge DR, Kim HR, **Ahn MJ**, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. *J Clin Oncol*. 2020 Nov 1;38(31):3592-3603
58. Papadimitrakopoulou VA, Mok TS, Han JY, **Ahn MJ**, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenzov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. *Ann Oncol*. 2020 Nov;31(11):1536-1544.
59. Kim S, Kim S, Park YS, Park JO, Lim HY, Ahn JS, Lee J, Sun JM, Kang WK, Han R, Kim J, **Ahn MJ**. Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. *Expert Opin Investig Drugs*. 2020 Sep;29(9):1059-1067.
60. **Ahn MJ**. Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use.
61. *J Thorac Oncol*. 2020 Sep;15(9):1399-1400

62. Seong M, Park S, Kim ST, Park SG, Kim YK, Kim HJ, **Ahn MJ**. Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR. *J Neurooncol.* 2020 Sep;149(2):367-372.
63. Park S, **Ahn MJ**. Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M? *Ann Oncol.* 2020 Nov;31(11):1582.
64. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenzov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected *EGFR*-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med.* 2020 Oct 29;383(18):1711-1723
65. Kim HR, Kang HN, Yun MR, Ju KY, Choi JW, Jung DM, Pyo KH, Hong MH, **Ahn MJ**, Sun JM, Kim HS, Kim J, Yoo J, Kim KR, Koh YW, Kim SH, Choi EC, Yoon SO, Shim HS, Paik S, Kim TM, Cho BC. Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. *Br J Cancer.* 2020 Dec;123(12):1720-1729.
66. Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, **Ahn MJ**, Park K, Lee SH, Park WY. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. *J Immunother Cancer.* 2020 Oct;8(2):e001199
67. Jung HA, Woo SY, Lee SH, Ahn JS, **Ahn MJ**, Park K, Sun JM. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. *Transl Lung Cancer Res.* 2020 Oct;9(5):1749-1758.
68. Jung HA, Park S, Sun JM, Lee SH, Ahn JS, **Ahn MJ**, Park K. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon *EGFR* Mutations: Are They Different from Those with Common *EGFR* Mutations? *Biology (Basel).* 2020 Oct 7;9(10):326. doi: 10.3390/biology9100326.

69. Lee J, Choi JY, Lim SW, **Ahn MJ**, Park K, Zo JI, Shim YM, Oh D, Sun JM. Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation. *Eur J Cardiothorac Surg.* 2020 Nov 1;58(5):1019-1026.
70. Koh J, Hur JY, Lee KY, Kim MS, Heo JY, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Regulatory (FoxP3⁺) T cells and TGF- β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. *Sci Rep.* 2020 Nov 4;10(1):18994. doi: 10.1038/s41598-020-76130-1.
71. So YK, Byeon SJ, Ku BM, Ko YH, **Ahn MJ**, Son YI, Chung MK. An increase of CD8⁺ T cell infiltration following recurrence is a good prognosticator in HNSCC. *Sci Rep.* 2020 Nov 18;10(1):20059. doi: 10.1038/s41598-020-77036-8.
72. Kim JH, Lee JW, Park K, **Ahn MJ**, Moon JW, Ham SY, Yi CA. Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. *Ann Palliat Med.* 2020 Nov 25;apm-19-622.
73. Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, **Ahn MJ**, Kim SB, Keam B. Correction to: Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. *J Cancer Res Clin Oncol.* 2020 Dec;146(12):3371.
74. Perets R, Bar J, Rasco DW, **Ahn MJ**, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR, Kotasek D, Gutierrez M, Niu J, Siddiqi S, Li X, Cyrus J, Chackerian A, Chain A, Altura RA, Cho BC. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. *Ann Oncol.* 2020 Dec 2:S0923-7534(20)43175-8.
75. Lee MH, Cho KR, Choi JW, Kong DS, Seol HJ, Nam DH, Jung HA, Sun JM, Lee SH, Ahn JS, **Ahn MJ**, Park K, Lee JI. Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. *J Korean Neurosurg Soc.* 2020 Dec 4. doi: 10.3340/jkns.2020.0135. Online ahead of print.
76. Lee YG, Chang H, Keam B, Chun SH, Park J, Park KU, Shin SH, An HJ, Lee KE, Lee KW, Kim HR, Kim SB, **Ahn MJ**, Hwang IG. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory

Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. *Cancer Res Treat.* 2020 Dec 7. doi: 10.4143/crt.2020.824. Online ahead of print.

77. Passaro A, Mok T, Peters S, Popat S, **Ahn MJ**, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. *J Thorac Oncol.* 2020 Dec 14;S1556-0864(20)31102-3. doi: 10.1016/j.jtho.2020.12.002. Online ahead of print.
78. Kim KH, Hur JY, Koh J, Cho J, Ku BM, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**, Shin EC. Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. *Immune Netw.* 2020 Dec 21;20(6):e48. doi: 10.4110/in.2020.20.e48. eCollection 2020 Dec.
79. Lee J, **Ahn MJ**. Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role? *Curr Opin Oncol.* 2021 Jan;33(1):64-72.
80. Ku BM, Kim Y, Lee KY, Kim SY, Sun JM, Lee SH, Ahn JS, Park K, **Ahn MJ**. Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. *Eur J Immunol.* 2021 Jan 28. doi: 10.1002/eji.202048966. Online ahead of print.
81. Park JH, You GL, **Ahn MJ**, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. *J Cancer Res Clin Oncol.* 2021 Feb 1. doi: 10.1007/s00432-021-03527-4. Online ahead of print.